<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405258</url>
  </required_header>
  <id_info>
    <org_study_id>947</org_study_id>
    <nct_id>NCT04405258</nct_id>
  </id_info>
  <brief_title>Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial</brief_title>
  <acronym>LEAP-AF</acronym>
  <official_title>Randomized Clinical Trial of Additional Left Atrial Posterior Wall Isolation for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical Effectiveness, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical Effectiveness, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose for this study is to determine whether left posterior wall isolation (PWI) in
      addition to pulmonary vein isolation (PVI) is effective as ablation strategy for persistent
      atrial fibrillation (AF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PVI is cornerstone of AF ablation. However, clinical outcome of only PVI in patients with
      persistent AF is insufficient due to AF substrate extending to left atrium. Strategy of
      catheter ablation for persistent AF is not established despite attempts of numerous left
      atrial substrate modifications. Additional PWI on PVI is one of expected effective strategies
      for persistent AF, because PW originated from common tissue of PV and is considered to play a
      part in AF trigger and maintenance. However, this strategy is also not established in the
      recent international consensus statement. Following two reasons are considered. One is the
      procedural difficulty in creating durable PWI, and another is the existence of patients who
      can recover by only PVI. The latest technology, ablation index, can create durable PVI, and
      may create durable PWI. Several reports suggested that PVI only strategy was sufficient in
      the patients with persistent AF who could maintain sinus rhythm after pharmacological or
      electrical cardioversion. Therefore, we planed this randomized clinical trial that compared
      between PVI alone and additional PWI on PVI using ablation index in the patients with
      persistent AF without pharmacological sinus rhythm conversion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of atrial tachyarrhythmia after 90-day blanking period of catheter ablation</measure>
    <time_frame>18 months</time_frame>
    <description>Recurrence of atrial tachyarrhythmia is defined atrial arrhythmia that needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial fibrillation or atrial tachycardia after 90-day blanking period of catheter ablation</measure>
    <time_frame>18 months</time_frame>
    <description>Recurrence of atrial fibrillation or atrial tachycardia needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial fibrillation or atrial tachycardia within 90-day after catheter ablation</measure>
    <time_frame>90 days</time_frame>
    <description>Recurrence of atrial fibrillation or atrial tachycardia needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeated ablation of atrial tachyarrhythmia</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial fibrillation or atrial tachycardia after 90-day blanking period of repeated ablation</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Quality of Life Questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Atrial Fibrillation Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of ablation procedure</measure>
    <time_frame>1 month</time_frame>
    <description>Complications of ablation procedure includes death, cardiac tamponade, pericardial effusion, systemic embolism, symptomatic strokes, hematoma, A-V shunt, pericarditis, phrenic nerve paralysis, A-V block, procedure-related infections, heart failure, atrio-esophageal fistula, esophageal vagus nerve injury</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <condition>Pulmonary Vein Isolation</condition>
  <condition>Posterior Wall Isolation</condition>
  <arm_group>
    <arm_group_label>PVI alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVI and PWI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <description>Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation</description>
    <arm_group_label>PVI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Left posterior wall isolation</intervention_name>
    <description>Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation</description>
    <arm_group_label>PVI and PWI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for first catheter ablation of persistent atrial fibrillation

          -  Patients without conversion to sinus rhythm within 30 days after antiarrhythmic drug
             administration

          -  Patients with persisting duration of atrial fibrillation less than 3 years

          -  Patients with left atrial diameter less than 50mm

          -  Patients who can be followed up for 18 months

          -  Patients with written informed consent

        Exclusion Criteria:

          -  Patients who can not be received adequate anticoagulation therapy

          -  Patients with history of myocardial infarction within 6 months

          -  Patients with history of open heart surgery

          -  Patients scheduled for open heart surgery

          -  Patients with severe valvular heart disease

          -  Patients during pregnancy

          -  Patients with expected life expectancy less than 1 year due to malignancy or
             non-cardiovascular disease

          -  Patients considered unsuitable for study by the attending physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keisuke Okawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kagawa Prefectural Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keisuke Okawa, MD</last_name>
    <phone>+81-87-811-3333</phone>
    <phone_ext>5555</phone_ext>
    <email>k-ookawa@chp-kagawa.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masahiko Takahashi, MD</last_name>
    <phone>+81-87-811-3333</phone>
    <phone_ext>5558</phone_ext>
    <email>ma-takahashi@chp-kagawa.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisuke Okawa, MD</last_name>
      <phone>+81-87-811-3333</phone>
      <phone_ext>5555</phone_ext>
      <email>k-ookawa@chp-kagawa.jp</email>
    </contact>
    <contact_backup>
      <last_name>Masahiko Takahashi, MD</last_name>
      <phone>+81-87-811-3333</phone>
      <phone_ext>5558</phone_ext>
      <email>ma-takahashi@chp-kagawa.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Posterior wall isolation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data that support the findings of this study will be available from the data center upon reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

